- South African variant might resist present antibody therapies
- Pfizer/BioNTech shot doubtless protects towards UK variant
- Immune system will keep in mind tips on how to make COVID-19 antibodies
- Mortality increased when ICUs are full of COVID-19 sufferers
The next is a roundup of a few of the newest scientific research on the novel coronavirus and efforts to seek out therapies and vaccines for COVID-19, the sickness brought on by the virus.
South African variant might resist present antibody therapies
The variant of the brand new coronavirus recognized in South Africa can resist, or “escape,” antibodies that neutralise earlier variations of the virus, scientists have discovered.
It “exhibits complete escape” from three courses of monoclonal antibodies manufactured for treating COVID-19 sufferers, and it reveals “substantial or complete” resistance to neutralising antibodies in blood donated by COVID-19 survivors, the scientists reported on Tuesday on bioRxiv forward of peer evaluate.
Similarities between the South Africa variant and one other variant recognized in Brazil recommend the Brazilian variant will present comparable resistance, they added.
Liam Smeeth of the London Faculty of Hygiene and Tropical Medication, who was not concerned within the examine, famous that these have been laboratory assessments, and it might be unwise to extrapolate the findings to people at this level.
“The data do raise the possibility that the protection gained from past infection with COVID-19 may be lower for re-infection with the South African variant,” he mentioned. “The data also suggest that the existing vaccines could be less effective against the South African variant.”
He known as for big research amongst populations the place the variant is frequent.
Pfizer/BioNTech shot doubtless protects towards UK variant
The COVID-19 vaccine from Pfizer Inc and BioNTech SE is more likely to defend towards the extra infectious variant of the virus found in Britain and now spreading world wide, in response to laboratory assessments.
Researchers took blood samples from 16 individuals who had obtained the vaccine and uncovered the blood to an artificial virus, or pseudovirus, that was engineered to have 10 mutations discovered within the UK variant. The antibodies that had developed in response to the vaccine successfully neutralized the pseudovirus, in response to a report posted on Tuesday on bioRxiv forward of peer evaluate.
“This makes it very unlikely that the UK variant will escape from the protection provided by the vaccine,” mentioned Jonathan Stoye, a virus scientist at Britain’s Francis Crick Institute who was not concerned within the analysis. Comparable experiments are wanted with the extra regarding variant first present in South Africa, he urged.
AstraZeneca Plc, Moderna Inc and CureVac NV are additionally testing whether or not their respective vaccines will defend towards the fast-spreading variants.
Immune system will keep in mind tips on how to make COVID-19 antibodies
Individuals who have recovered from COVID-19 can doubtless mount a quick and efficient response to the virus in the event that they encounter it once more as a result of their immune system’s “B cells” will keep in mind tips on how to make the antibodies wanted to battle it, a brand new examine reveals.
Researchers tracked 87 COVID-19 survivors for six months and located that whereas ranges of antibodies to the virus might decline over time, the variety of reminiscence B cells stays unchanged.
The antibodies produced by these cells are stronger than the sufferers’ unique antibodies and could also be extra proof against mutations within the spike protein the virus makes use of to interrupt into cells, they mentioned. For instance, they discovered, the antibodies may acknowledge and neutralize at the least one of many mutations within the South African variant of the virus that has triggered concern amongst well being consultants.
Even when antibody ranges fall, B cells will keep in mind tips on how to make them when vital, in response to examine chief Michel Nussenzweig of Rockefeller College, whose findings have been reported on Monday in Nature.
If that is true at six months, as on this examine, it’s secure to imagine it’s in all probability nonetheless true for longer intervals, he added. Individuals who have recovered from COVID-19 “may become infected but the immune system will be prepped to fight off the infection,” Nussenzweig mentioned.
Mortality increased when ICUs are full of COVID-19 sufferers
The extra full an intensive care unit (ICU) is with COVID-19 sufferers, the upper the mortality charge amongst these sufferers, new knowledge recommend.
When researchers tracked outcomes of 8,515 COVID-19 sufferers admitted to 88 US Veterans Affairs hospitals in 2020, they discovered that survival charges improved between March and August.
All through the examine interval, nonetheless, the danger of dying was practically double when at the least 75% of ICU beds have been crammed with COVID-19 sufferers, in comparison with once they accounted for not more than 25% of ICU beds.
COVID-19 mortality “increases during periods of peak demand,” mentioned Dr. Daybreak Bravata of the Richard L Roudebush VA Medical Middle in Indianapolis who co-led the examine printed on Tuesday in JAMA Community Open. “The more the public can do to avoid infections, the better,” she added.
As well as, Bravata mentioned, “facilities within a healthcare system or within a geographic region should collaborate to triage critically ill patients with COVID-19 to sites with greater ICU capacity to reduce strain on any one facility.”